Physician profile
Jared Hara
NPI 1548751894
$3,409.66
in general payments reported to CMS, 2019-2025
22 companies · $1,583 in 2025
The $1,583 reported for 2025 was more than what 88% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $416 · 2022: $25.27 · 2023: $167 · 2024: $1,218 · 2025: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,844 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,843.79 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $124.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $631.75 | 2023-2025 | Imfinzi, Lynparza, Enhertu |
| Novocure INC. | $617.49 | 2021-2025 | Optune Gio, Optune |
| Janssen Biotech, INC. | $242.89 | 2024-2025 | Erleada, Darzalex, Tecvayli |
| Teleflex LLC | $239.40 | 2024-2025 | Barrigel |
| Merck Sharp & Dohme LLC | $212.33 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| Fujifilm Healthcare Americas Corporation | $204.55 | 2024 | Utaswako Afp-L3 |
| Sumitomo Pharma America, INC. | $190.47 | 2024 | Orgovyx |
| Monteris Medical Corporation | $178.98 | 2025 | Neuroblate |
| Novartis Pharmaceuticals Corporation | $142.88 | 2024-2025 | |
| Pfizer INC. | $116.80 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $101.03 | 2023-2025 | Opdivo |
| Eisai INC. | $95.96 | 2024-2025 | |
| Glaxosmithkline, LLC. | $91.93 | 2023 | Jemperli |
| Astellas Pharma US INC | $80.73 | 2024-2025 | Vyloy, Xtandi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.51 | 2024-2025 | Gilotrif |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $45.22 | 2022-2023 | Spaceoar Vue System - 10ml |
| Blue Earth Diagnostics | $35.03 | 2021 | |
| Aveo Pharmaceuticals, INC. | $30.39 | 2025 | |
| Pharmacosmos Therapeutics INC. | $26.73 | 2025 | Monoferric |
| Recordati_rare_diseases_inc. | $23.66 | 2024 | Sylvant |
| Daiichi Sankyo INC. | $19.93 | 2025 | Enhertu |
| Impedimed, INC. | $17.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Hara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.